Are Obesity Drugs a Lost Cause in Europe?

Arena Pharmaceuticals had a rough quarter, but the results don't really matter. The company is waiting on DEA scheduling before it can start selling its obesity drug, Belviq. However, there's one place Belviq isn't going on sale anytime soon: Europe. Arena is voluntarily pulling Belviq from the approval process, with no set timetable for resubmission.

VIVUS, meanwhile, has seen Qsymia get rejected in Europe, and in the following video, health-care analyst David Williamson looks at whether any of the new obesity drugs have an EU approval in their future. Watch and find out what it all means for investors.


Who will win the obesity drug market?
Can VIVUS pick up its lagging sales and fend off the competition, or will Arena Pharmaceuticals reign supreme in the obesity space? If you're in the dark, grab copies of The Motley Fool's premium research reports on VIVUS and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and VIVUS -- complete with a full year of free updates -- today.

The article Are Obesity Drugs a Lost Cause in Europe? originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Small Cap Investing

Learn now to invest in small companies the right way.

View Course »

Investing in Emerging Markets

Learn to invest in a globalized world.

View Course »

Add a Comment

*0 / 3000 Character Maximum